Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

The Motley Fool

21 Jul 2026, 00:18 UTC · 9h ago

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Corcept Therapeutics raised its full-year revenue guidance to as much as $1.05 billion. — Upwardly revised financial guidance is a strong fundamental catalyst for stock price appreciation.
+0.60
2
The FDA approved relacorilant (Lifyorli) for the treatment of ovarian cancer. — Product approvals expand the addressable market and create new revenue streams for pharmaceutical companies.
+0.50
3
CFO Mokari Atabak sold 40,000 shares of Corcept Therapeutics on July 15, 2026. — Insider selling can be viewed negatively, though the text notes this was a pre-arranged plan.
-0.20
4
The CFO's equity compensation is heavily weighted toward options (nearly 180,000) relative to outright shares (16,130). — High option leverage aligns the executive's incentives strongly with significant stock price growth.

6 related stories

The Motley Fool
9h ago
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
- fda approval
- guidance
- healthcare
Read

Corcept's CFO Set His Sel… — CORT +0.60 | NewsImpactScreener

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

What matters in this story

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

What matters in this story

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Novartis Q2 surpasses estimates despite 50% Entresto sales drop

What This Evolv Insider Sale Signals to Long-Term Investors as Revenue Jumped 45%

What This Grindr Insider Sale Signals For Long-Term Investors

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

What matters in this story

Next reads from the same story arc

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

What matters in this story

Next reads from the same story arc

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Novartis Q2 surpasses estimates despite 50% Entresto sales drop

What This Evolv Insider Sale Signals to Long-Term Investors as Revenue Jumped 45%

What This Grindr Insider Sale Signals For Long-Term Investors

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting